2025
Quality of gastrointestinal surgical oncology care according to insurance status
Butensky S, Kerekes D, Bakkila B, Billingsley K, Ahuja N, Johnson C, Khan S. Quality of gastrointestinal surgical oncology care according to insurance status. Journal Of Gastrointestinal Surgery 2025, 29: 101961. PMID: 39800081, DOI: 10.1016/j.gassur.2025.101961.Peer-Reviewed Original ResearchConceptsMedicare-insured patientsNational Cancer DatabaseAdequate lymphadenectomyNegative marginsCancer DatabaseRetrospective study of adult patientsStudy of adult patientsSurvival analysisInsurance statusReceipt of lymphadenectomyCurative-intent resectionGastrointestinal (GI) cancersIncreased risk of deathMultivariate survival analysisAdequacy of lymphadenectomyCox proportional hazards modelsRisk of deathProportional hazards modelResection marginsSurgical oncology careAdjuvant therapyRetrospective studyAdult patientsBiliary organismsLymphadenectomy
2024
Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply